Smith & Nephew plc (LON:SN)
London
· Delayed Price · Currency is GBP · Price in GBp | Market Cap | 9.31B |
| Revenue (ttm) | 4.64B |
| Net Income (ttm) | 329.09M |
| Shares Out | 875.04M |
| EPS (ttm) | 0.38 |
| PE Ratio | 28.35 |
| Forward PE | 14.34 |
| Dividend | 0.28 (2.62%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 2,221,690 |
| Average Volume | 2,541,681 |
| Open | 1,070.00 |
| Previous Close | 1,064.50 |
| Day's Range | 1,064.00 - 1,075.00 |
| 52-Week Range | 911.00 - 1,245.26 |
| Beta | 0.62 |
| RSI | 52.72 |
| Earnings Date | Jul 31, 2025 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2024, Smith & Nephew's revenue was $5.81 billion, an increase of 4.70% compared to the previous year's $5.55 billion. Earnings were $412.00 million, an increase of 56.65%.
Financial numbers in USD Financial StatementsNews
Smith+Nephew wins a DoD supply contract worth up to $75M
Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, has been selected to provide its RENASYS◊ TOUCH Negative Pressure Wound Therapy (NPWT) Systems under a single award, 10-year* co...
Study shows patients treated with Smith+Nephew's CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*
The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week
Smith+Nephew to showcase its CORI™ Surgical System at surgical clinics across Germany, Austria and Switzerland
“CORI on Tour” will highlight the latest advancements in robotics-assisted surgery for hip and knee joint replacement Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today anno...
Smith & Nephew plc (SNN) Q1 2025 Earnings Call Transcript
Smith & Nephew: Underappreciated Recovery With Strategic Upside
Smith & Nephew is undergoing a turnaround under CEO Deepak Nath, focusing on margin expansion and growth. See why I rate SNN stock a Buy now.
Trump tariffs: these two European healthcare stocks face the highest US revenue exposure
Global financial markets are in turmoil this morning after the US President announced sweeping tariffs on several countries in a push to lower the nation's trade deficit. Trump's new tariffs are parti...
Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Sur...
Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest advancements in Sports Medicine for joint repair at the American Academy of Orthopae...
Smith & Nephew PLC (SNN) Achieves Milestone in Hip Replacement Technology
Smith & Nephew PLC (SNN) Achieves Milestone in Hip Replacement Technology
New report confirms Smith+Nephew's OXINIUM™ Technology is the best performing bearing surface at 20 years for total hip arthroplasty
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce that the latest annual report from the Australian Orthopaedic Association National Joint Replacement Regi...
Smith & Nephew gains after report it may evaluate a break-up
Wound Care Market Size is Expected to Reach USD 32.75 Billion by 2033, Growing at a CAGR of 3.94%: Straits Research
The global wound care market size was valued at USD 23.13 billion in 2024 and is projected to reach from USD 24.04 billion in 2025 to USD 32.75 billion by 2033, growing at a CAGR of 3.94% during the f...
MARKET REPORT: Recovery hopes breathe life into hip replacement maker Smith & Nephew
Smith & Nephew shares rose 10% in early trading before ending the day up 6.1%, or 64p, to 1107.5p. That took gains for the year to nearly 11%.
We are having constructive engagement with activist shareholders, says Smith & Nephew CEO
Deepak Nath, CEO of Smith & Nephew discusses spin offs, navigating the China market, and the medical tech firm's full-year earnings for 2024.
Smith & Nephew plc (SNN) Q4 2024 Earnings Call Transcript
Smith & Nephew plc 2024 Q4 - Results - Earnings Call Presentation
Smith & Nephew Non-GAAP EPS of $0.843, revenue of $5.81B
We are having constructive engagement with activist shareholders, says Smith & Nephew CEO
Deepak Nath, CEO of Smith & Nephew discusses, spin offs, navigating the China market, and the medical tech firm's full-year earnings for 2024.
Hip replacement firm Smith & Nephew’s profit surges amid recovery in US sales
The medical technology giant has been in the midst of a turnaround effort, and recently faced calls from its top investors to break the company up.
Smith & Nephew Shares Rise After Higher Profit, Revenue Offset China Headwinds
Earnings Scheduled For February 25, 2025
Companies Reporting Before The Bell • Super Group (SGHC) (NYSE: SGHC) is estimated to report earnings for its fourth quarter. • Carter's (NYSE: CRI) is expected to report quarterly earnings at $1.90...
UK Stock Market News: On The Beach, Unite Group, Smith & Nephew
On The Beach expects a strong summer, return of overseas students boosts Unite, Smith & Nephew outlook upbeat in full year results
UK's Smith+Nephew beats annual profit expectations
Smith+Nephew beat analysts' expectations for annual sales and profit on Tuesday, as a recovery in its U.S. knee and hip implant business, along with cost cuts, helped the medical products maker offset...
